The once-popular genetic testing company is being acquired by a nonprofit led by a 23andMe co-founder, as questions persist about how to remove personal data from it.

DNA firm 23andMe fined £2.31m by UK regulator for a 2023 data breach that exposed sensitive health and family information. Sale to TTAM Research to include stricter privacy commitments.

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

Regeneron Pharmaceuticals had previously agreed to acquire the company for $256 million. TTAM’s higher bid and added consumer protections ultimately led the board’s special committee to select it as ...

In a recent investigation we took a hard look at the cybersecurity practices of major direct-to-consumer DNA testing ...

A nonprofit led by the co-founder and former CEO of 23andMe outbid competitors for nearly all of the company’s assets.

Testing firm 23andMe has been fined more than £2m for failing to protect the sensitive personal and genetic data of more than ...

Anne Wojcicki, founder of 23andMe, has successfully repurchased the genetic testing firm out of bankruptcy through her ...

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

June 13 (Reuters) - Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals’ REGN.O offer for the DNA-testing company ...

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.